Philips Takes a Firm Stand in the DCB Market with ILLUMENATE

This study will look at findings that continue to demonstrate the benefits of the Stellarex 0.014 Drug-Coated Balloon for BTK PAD and its safety and durability for patients. Given the challenging chronic nature of BTK PAD, we are hoping to find that through sustained patency using Stellarex, we can improve healing, and reduce target lesion revascularization and major amputation." Layout of the Land C.R. Bard once held the crown in the DCB market, having gained approval for its Lutonix technology in 2014. The Murray Hill, NJ-based company began losing share when Medtronic launched the IN.PACT Admiral in early 2015. (Editor’s note: Bard was eventually acquired by Becton Dickinson and Company for $24 billion in 2017.) Medtronic quickly became the dominant player because of significant clinical outcomes and low drug dose, as well as the new indications for long lesions and in-stent restenosis (ISR) obtained in July and September of 2016, respectively. Medtronic also received a nod from FDA for the IN.PACT Admiral DCB to treat long superficial femoral artery (SFA) lesions up to 360mm Not to be left out of the growing market opportunity DCBs present, Abbott Laboratories sharpened its sights on the market when it obtained the commercialization rights for SurVeil drug-coated vascular balloon from Surmodics. The deal was for up to $92 million. Finally, Boston Scientific, the undisputed leader of tuck-in acquisitions for 2018, announced that it was eyeing 2020 to pote...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news